Depletion of uric acid due to SLC22A12 (URAT1) loss-of-function mutation causes endothelial dysfunction in hypouricemia

Circulation Journal

Volumn 79, Issue 5, 2015, Pages 1125-1132

  Sugihara, Shinobu ^a   Hisatome, Ichiro ^b   Kuwabara, Masanari ^c   Niwa, Koichiro ^c   Maharani, Nani ^b   Kato, Masahiko ^a   Ogino, Kazuhide ^d   Hamada, Toshihiro ^e   Ninomiya, Haruaki ^a   Higashi, Yukihito ^f   Ichida, Kimiyoshi ^g   Yamamoto, Kazuhiro ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

^c ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^d TOTTORI UNIVERSITY HOSPITAL   (Japan)

^e Department of Regional Medicine ^*  (Japan)

^f HIROSHIMA UNIVERSITY   (Japan)

^g TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Hypouricemia; Uric acid; Uric acid transporter 1; Vascular function

Indexed keywords

CREATININE; GENOMIC DNA; MESSENGER RNA; URIC ACID; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; SLC22A12 PROTEIN, HUMAN;

ADULT; AGED; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; BLOOD VESSEL PARAMETERS; CARDIO ANKLE VASCULAR INDEX; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; ECHOGRAPHY; ENDOTHELIAL DYSFUNCTION; FEMALE; FLOW MEDIATED DILATION; GENE; GENE EXPRESSION; GENOME; GENOTYPE; HETEROZYGOSITY; HUMAN; HUMAN CELL; HYPOURICEMIA; LOSS OF FUNCTION MUTATION; MALE; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; UA TRANSPORTER 1 GENE; URINALYSIS; BLOOD; GENETICS; HETEROZYGOTE; KIDNEY TUBULE DISORDER; MIDDLE AGED; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; UMBILICAL VEIN ENDOTHELIAL CELL; UROLITHIASIS; VASCULAR ENDOTHELIUM; VASODILATATION;

ADULT; ENDOTHELIUM, VASCULAR; FEMALE; HETEROZYGOTE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MIDDLE AGED; MUTATION; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; RENAL TUBULAR TRANSPORT, INBORN ERRORS; URIC ACID; URINARY CALCULI; VASODILATION;

EID: 84928501124     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-1267     Document Type: Article

References (41)

1. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Uric acid restores endothelial function in patients with type 1 diabetes and regular smokers. Diabetes 2006; 55: 3127-3132.
2. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078.
3. De Leeuw PW, Thijs L, Birkenhäger WH, Voyaki SM, Efstratopoulos AD, Fagard RH, et al; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: Results from the Syst-Eur trial. J Am Soc Nephrol 2002; 13: 2213-2222.
4. Kuo L, Davis MJ, Cannon MS, Chilian WM. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation: Restoration of endothelium-dependent responses by L-arginine. Circ Res 1992; 70: 465-476.
5. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. Int Angiol 2002; 21: 109-116.
6. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radicalcaused aging and cancer: A hypothesis. Proc Natl Acad Sci USA 1981; 78: 6858-6862.
7. Sevanian A, Davies KJ, Hochstein P. Serum urate as an antioxidant for ascorbic acid. Am J Clin Nutr 1991; 54: 1129S-1134S.
8. Nieto FJ, Iribarren C, Gross MD, Comstock GW, Cutler RG. Uric acid and serum antioxidant capacity: A reaction to atherosclerosis? Atherosclerosis 2000; 148: 131-139.
9. Lee SH, Heo SH, Kim JH, Lee D, Lee JS, Kim YS, et al. Effects of uric acid levels on outcome in severe ischemic stroke patients treated with intravenous recombinant tissue plasminogen activator. Eur Neurol 2013; 71: 132-139.
10. Sperling O. Hereditary renal hypouricemia. Mol Genet Metab 2006; 89: 14-18.
11. Pitocco D, Di Stasio E, Romitelli F, Zaccardi F, Tavazzi B, Manto A, et al. Hypouricemia linked to an overproduction of nitric oxide is an early marker of oxidative stress in female subjects with type 1 diabetes. Diabetes Metab Res Rev 2008; 24: 318-323.
12. Thijssen DH, Black MA, Pyke KE, Padilla J, Atkinson G, Harris RA, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol 2011; 300: H2-H12.
13. Inaba Y, Chen JA, Bergmann SR. Prediction of future cardiovascular outcomes by flow-mediated vasodilatation of brachial artery: A meta-analysis. Int J Cardiovasc Imaging 2010; 26: 631-640.
14. Poredos P, Jezovnik MK. Testing endothelial function and its clinical relevance. J Atheroscler Thromb 2013; 20: 1-8.
15. Ichida K, Hosoyamada M, Hisatome I, Enomoto A, Hikita M, Endou H, et al. Clinical and molecular analysis of patients with renal hypouricemia in Japan-influence of URAT1 gene on urinary urate excretion. J Am Soc Nephrol 2004; 15: 164-173.
16. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-26838.
17. Kato M, Hisatome I, Tomikura Y, Kotani K, Kinugawa T, Ogino K, et al. Status of endothelial dependent vasodilation in patients with hyperuricemia. Am J Cardiol 2005; 96: 1576-1578.
18. Shirai K, Utino S, Otsuka K, Takata M. A novel blood pressureindependent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb 2006; 13: 101-107.
19. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality, The NHANES 1 epidemiology follow-up study, 1971–1992. JAMA 2000; 283: 2404-2410.
20. Niizeki T, Takeishi Y, Arimoto T, Okuyama H, Nozaki N, Hirono O, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol 2006; 47: 219-228.
21. Lin GM, Li YH, Zheng NC, Lai CP, Lin CL, Wang JH, et al. Serum uric acid as an independent predictor of mortality in high-risk patients with obstructive coronary artery disease: A prospective observational cohort study from the ET-CHD registry, 1997–2003. J Cardiol 2013; 61: 122-127.
22. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol 2005; 25: 29-38.
23. George J, Struthers AD. Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag 2009; 5: 265-272.
24. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.
25. Li S, Sanna S, Maschio A, Busonero F, Usala G, Mulas A, et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007; 3: e194, doi:10.1371/journal.pgen.0030194.
26. Dinour D, Gray NK, Campbell S, Shu X, Sawyer L, Richardson W, et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010; 21: 64-72.
27. Kamatani Y, Matsuda K, Okada Y, Kubo M, Hosono N, Daigo Y, et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet 2010; 42: 210-215.
28. Berry CE, Hare JM. Xanthine oxidoreductase and cardiovascular disease: Molecular mechanisms and pathophysiological implications. J Physiol 2004; 555: 589-606.
29. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516.
30. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 2002; 106: 221-226.
31. Das DK, Engelman RM, Clement R, Otani H, Prasad MR, Rao PS. Role of xanthine oxidase inhibitor as free radical scavenger: A novel mechanism of action of allopurinol and oxypurinol in myocardial salvage. Biochem Biophys Res Commun 1987; 148: 314-319.
32. Price KL, Sautin YY, Long DA, Zhang L, Miyazaki H, Mu W, et al. Human vascular smooth muscle cells express a urate transporter. J Am Soc Nephrol 2006; 17: 1791-1795.
33. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidasemediated oxidative/nitrosative stress. Am J Physiol Cell Physiol 2007; 293: C584-C596.
34. Van Peenen HJ. Causes of hypouricemia. Ann Intern Med 1973; 78: 977-978.
35. Hisatome I, Ogino K, Kotake H, Ishiko R, Saito M, Hasegawa J, et al. Cause of persistent hypouricemia in outpatients. Nephron 1989; 51: 13-16.
36. Yanase M, Nakahama H, Mikami H, Fukuhara Y, Orita Y, Yoshikawa H. Prevalence of hypouricemia in apparently normal population. Nephron 1988; 48: 80.
37. Komoda F, Sekine T, Inatomi J, Enomoto A, Endou H, Ota T, et al. The W258X mutation in SLC22A12 is the predominant cause of Japanese renal hypouricemia. Pediatr Nephrol 2004; 19: 728-733.
38. Ichida K, Hosoyamada M, Kamatani N, Kamitsuji S, Hisatome I, Shibasaki T, et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 2008; 74: 243-251.
39. Cheong HI, Kang JH, Lee JH, Ha IS, Kim S, Komoda F, et al. Mutational analysis of idiopathic renal hypouricemia in Korea. Pediatr Nephrol 2005; 20: 886-890.
40. Dinour D, Bahn A, Ganon L, Ron R, Geifman-Holtzman O, Knecht A, et al. URAT1 mutations cause renal hypouricemia type 1 in Iraqi Jews. Nephrol Dial Transplant 2011; 26: 2175-2181.
41. Matsuzawa Y, Sugiyama S, Sugamura K, Sumida H, Kurokawa H, Fujisue K, et al. Successful diet and exercise therapy as evaluated on self-assessment score significantly improves endothelial function in metabolic syndrome patients. Circ J 2013; 77: 2807-2815.